Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: February 9, 2023

Details for Patent: 6,902,742

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 6,902,742
Title: Multiparticulate modified release composition
Abstract:The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.
Inventor(s): Devane; John G. (Athlone, IE), Stark; Paul (Athlone, IE), Fanning; Niall M. M. (Athlone, IE), Rekhi; Gurvinder Singh (Suwanee, GA)
Assignee: Elan Corporation, plc (Dublin, IE)
Application Number:10/331,754
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,902,742
Patent Claim Types:
see list of patent claims
Composition; Delivery; Formulation; Dosage form; Use;

Drugs Protected by US Patent 6,902,742

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,902,742

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 021858 See Plans and Pricing
Austria 411011 See Plans and Pricing
Australia 1335000 See Plans and Pricing
Australia 2004202078 See Plans and Pricing
Australia 2005247019 See Plans and Pricing
Australia 2006285349 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.